Last $37.97 USD
Change Today -0.36 / -0.94%
Volume 2.1M
MYGN On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

320 Wakara Way

Salt Lake City, UT 84108

United States

Phone: 801-584-3600

Fax: 801-584-3640

Myriad Genetics, Inc. operates as a molecular diagnostic company. The company offers nine commercial molecular diagnostic tests, including six predictive medicine tests, two personalized medicine tests, and one prognostic medicine test. The company also markets its BRACAnalysis, COLARIS, COLARIS AP, and Prolaris tests through its own European sales force and has entered into marketing collaborations and distributor agreements with other organizations in selected Latin American, European, Asian and African countries. Molecular Diagnostic Tests The company’s molecular diagnostic tests are designed to analyze genes, their mutations, expression levels and proteins to assess an individual’s risk for developing disease later in life, determine a patient’s likelihood of responding to a particular drug, and assess a patient’s risk of disease progression and disease recurrence. The company offers nine primary commercial molecular diagnostic tests. The company’s commercial molecular diagnostic tests are: BRACAnalysis: A predictive medicine test for hereditary breast and ovarian cancer. The company’s BRACAnalysis test is an analysis of the BRCA1 and BRCA2 genes for assessing a woman’s risk of developing hereditary breast and ovarian cancer. Additionally, BRACAnalysis may be used to assist patients already diagnosed with breast or ovarian cancer and their physicians in determining the most appropriate therapeutic interventions to address their disease. The company owns or has exclusive rights to 24 U.S. patents covering BRACAnalysis testing. BART (BRACAnalysis Large Rearrangement Test): A predictive medicine test for hereditary breast and ovarian cancer. The company’s BART test is a predictive medicine test for detecting large genomic rearrangements in the genes involved in hereditary breast and ovarian cancer patients. The company owns seven U.S. patents covering BART testing. COLARIS: A predictive medicine test for hereditary colorectal cancer and uterine cancer. The company’s COLARIS test is an analysis of the MLH1, MSH2, MSH6, PMS2, EPCAM and MYH genes for assessing a person’s risk of developing colorectal cancer or uterine cancer. Through proper application of screening and polyp removal, colon cancer is a preventable disease. The company owns or has non-exclusive licensed rights to eight U.S. patents covering COLARIS testing. COLARIS AP: A predictive medicine test for hereditary colorectal cancer. Its COLARIS AP test detects mutations in the APC and MYH genes, which cause a colon polyp-forming syndrome known as Familial Adenomatous Polyposis (FAP), a more common variation of the syndrome known as attenuated FAP, and the MYH-associated polyposis signature (MAP). The company owns or has exclusive rights to ten U.S. patents covering COLARIS AP testing. MELARIS : A predictive medicine test for hereditary melanoma. The company’s MELARIS test analyzes mutations in the p16 gene to determine genetic susceptibility to malignant melanoma. Individuals who test positive for a deleterious mutation in the p16 gene with the MELARIS test have a 75-fold increased risk of developing melanoma during their lifetimes as compared to the general population. The company owns or has license rights to five U.S. patents covering MELARIS testing. PANEXIA: A predictive medicine test for pancreatic cancer. The company’s PANEXIA test is a comprehensive analysis of the PALB2 and BRCA2 genes for assessing a person’s risk of developing pancreatic cancer later in life. If an individual with a family history of pancreatic cancer receives the PANEXIA test and is identified as having a deleterious mutation, increased surveillance and other predictive steps can be taken in an effort to detect the cancer at an early stage where it may be more treatable. The company owns or has exclusive patent rights to 10 U.S. patent applications covering PANEXIA testing. PREZEON: A personalized and prognostic medicine test for cancer. The company’s PREZEON test is an immunohistochemistry test that analyzes the PTEN gene and assesses loss of PTEN function in many cancer types. The PTEN gene is one of the most important tumor suppressor genes and its lo

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYGN:US $37.97 USD -0.36

MYGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Reference Labs Inc $27.20 USD -0.19
Foundation Medicine Inc $26.54 USD -0.64
Genomic Health Inc $26.81 USD -0.02
Imperial Innovations Group PLC 447.50 GBp -5.00
QIAGEN NV €14.80 EUR -0.043
View Industry Companies
 

Industry Analysis

MYGN

Industry Average

Valuation MYGN Industry Range
Price/Earnings 16.4x
Price/Sales 3.9x
Price/Book 4.2x
Price/Cash Flow 14.8x
TEV/Sales 3.3x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYRIAD GENETICS INC, please visit www.myriad.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.